Inetetamab combined with tegafur as second-line treatment for human epidermal growth factor receptor-2-positive gastric cancer: A case report

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 4

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Cases. Feb 6, 2024; 12(4): 820-827
Published online Feb 6, 2024. doi: 10.12998/wjcc.v12.i4.820

Full Size Figure Download Figure

Figure 5 Variation in cancer antigen 199 levels during second-line treatment.

Citation: Zhou JH, Yi QJ, Li MY, Xu Y, Dong Q, Wang CY, Liu HY. Inetetamab combined with tegafur as second-line treatment for human epidermal growth factor receptor-2-positive gastric cancer: A case report. World J Clin Cases 2024; 12(4): 820-827
URL: https://www.wjgnet.com/2307-8960/full/v12/i4/820.htm
DOI: https://dx.doi.org/10.12998/wjcc.v12.i4.820

Zhou JH, Yi QJ, Li MY, Xu Y, Dong Q, Wang CY, Liu HY. Inetetamab combined with tegafur as second-line treatment for human epidermal growth factor receptor-2-positive gastric cancer: A case report. World J Clin Cases 2024; 12(4): 820-827 [PMID: 38322681 DOI: 10.12998/wjcc.v12.i4.820]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.